ADC Therapeutics rises as newly approved cancer drug brings in nearly $4 mln in sales

ADC Therapeutics SA

03/08/2021 17:17

** Shares of biotech co  ADCT.N  rise as much as 7% to
$22.15
    ** ADCT says its lead cancer drug ZYNLONTA generated net
sales of $3.8 mln in the two-month period after its approval
from FDA in April  urn:newsml:reuters.com:*:nBw1YbHgxa
    ** Co posts adjusted loss of 70 cents/share for Q2, compared
with analysts' estimates of a loss of 86 cents/share - Refinitiv
IBES data
    ** Including Tuesday's session, stock down about 32% this
year 

 (Reporting by Bhanvi Satija)
 ((Bhanvi.Satija@thomsonreuters.com;))